

## Biography

Dr Elza de Bruin is Director Translational Medicine at AstraZeneca, focusing her research on identifying cancer patients most likely to benefit from investigational treatments through use of circulating tumour DNA analyses. Elza obtained her PhD in Molecular Biology at Leiden University in The Netherlands and continued her career as postdoctoral fellow in the lab of Prof. Julian Downward at the CRUK–London Research Institute, where she discovered a novel escape route that lung cancers employ to survive anti-cancer treatment. She then obtained a postdoctoral fellowship in the lab of Prof. Charles Swanton at UCL London where she studies lung cancer evolution through multi-region sequencing analyses. Her work led to various high-impact scientific publications. Inspired by AstraZeneca’s vision to change the lives of cancer patients through scientific achievements, Elza joined AstraZeneca in 2015. In her role as Translational Medicine Lead, Elza is accountable for the patient selection strategy of clinical studies and exploratory biomarker research on patient samples with a primary focus on breast cancer.